Although additional well design ed , worldwide , placebo-controlled and r and omized studies are necessary to confirm the long-term outcomes of naftopidil pharmacotherapy , current data suggest that naftopidil administration in BPH patients provides comparable improvements in total IPSS , QoL , and urinary symptoms from baseline relative to 0.2 mg/d tamsulosin and 8 mg/d silodosin .
However , improvements in Qmax are generally less with naftopidil than with tamsulosin .
Reported adverse effects related to naftopidil administration are negligible and usually mild .
OBJECTIVES The aim of the study was to systematic ally review the effects of the adrenoreceptor A1D antagonist naftopidil in the management of  lower urinary tract symptoms ( LUTS ) .
α1-Adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume
Objectives To examine the mechanism underlying improvements in nocturia by α1-blockers , we investigated whether the α1-blocker naftopidil acts on nocturia with sleep disturbance using a frequency/volume chart ( FVC ) . Methods A total of 56 male patients with lower urinary tract symptoms were enrolled . The inclusion criteria were as follows : eight or more points on the I-PSS ; three or more points on the I-PSS score for nocturia ; and prostate volume larger than 20 ml . Patients received 50 mg of naftopidil once daily for 4 weeks , and non-responders received 75 mg for another 4 weeks . All patients were examined , and their data entered into FVC for 2 days before and after administration of naftopidil . Quality of sleep was also evaluated using modified Pittsburgh sleep quality index ( PSQI ) . Results Patients  with sleep quality scores of three or four were assigned to sleep disturbance group ( n = 33 ) , while those with scores of less than three were assigned to non-disturbance group ( n = 23 ) . After administration of naftopidil , total I-PSS decreased and nocturia score decreased from 3.5 to 2.6 ( P < 0.01 ) . Total mean score of modified PSQI in sleep disturbance group became significantly lower after administration of naftopidil ( from 16.9 to 14.0 ; P < 0.01 ) . Naftopidil significantly decreased nocturnal urine volume , result ing in a decrease in the nocturnal polyuria index in both sleep disturbance and non-disturbance groups . Conclusion These results suggest that α1-blockers have the ability to normalize sleep disorders . Naftopidil  improved nocturnal polyuria regardless of the presence of sleep disturbance , meaning that it might directly reduce nocturnal urine production
Although additional well design ed , worldwide , placebo-controlled and r and omized studies are necessary to confirm the long-term outcomes of naftopidil pharmacotherapy , current data suggest that naftopidil administration in BPH patients provides comparable improvements in total IPSS , QoL , and urinary symptoms from baseline relative to 0.2 mg/d tamsulosin and 8 mg/d silodosin .
However , improvements in Qmax are generally less with naftopidil than with tamsulosin .
Reported adverse effects related to naftopidil administration are negligible and usually mild .
OBJECTIVES The aim of the study was to systematic ally review the effects of the adrenoreceptor A1D antagonist naftopidil in the management of  lower urinary tract symptoms ( LUTS ) .